Mach 1 Financial Group LLC Purchases Shares of 13,022 Bristol Myers Squibb Company $BMY

Mach 1 Financial Group LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 13,022 shares of the biopharmaceutical company’s stock, valued at approximately $702,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter worth about $25,000. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares during the period. EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $32,000. KERR FINANCIAL PLANNING Corp bought a new position in Bristol Myers Squibb during the 3rd quarter valued at approximately $35,000. Finally, Garner Asset Management Corp purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $35,000. 76.41% of the stock is owned by institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to roll out Claude Enterprise across its global operations, giving more than 30,000 employees access to AI tools aimed at speeding up drug discovery, development, manufacturing, and commercial work. Article: Bristol Myers Squibb Announces Strategic Agreement with Anthropic
• Positive Sentiment: The company said it will unveil new data at ASCO 2026, highlighting the strength of its oncology portfolio and next-generation pipeline, which could reinforce confidence in future cancer-drug growth. Article: Bristol Myers Squibb to Unveil New Data at ASCO 2026
• Neutral Sentiment: Market commentary continues to center on the balance between Bristol Myers Squibb’s pipeline potential and patent-expiration risks, keeping investor sentiment tied to upcoming data readouts and execution. Article: How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BMY shares. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Barclays initiated coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. UBS Group restated a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Trading Up 1.8%

BMY opened at $59.58 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The stock has a market cap of $121.67 billion, a PE ratio of 16.74, a PEG ratio of 0.17 and a beta of 0.26. The business has a 50 day moving average of $58.47 and a 200-day moving average of $55.83.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.